MAINZ BIOMED B.V. MYNZ 深 沪
已收盘 12-12 16:00:00 美东时间
1.03
-0.020
-1.90%
华盛通- 最 高1.07
- 今 开1.04
- 成交量 20.37万股
- 最 低 0.995
- 昨 收 1.05
- 总市值 700.41万
- 52周最高 8.20
- 市盈率 静 --
- 换手率 3.00%
- 52周最低 0.92
- 委 比 -29.58%
- 总股本 680.01万
- 历史最高 1200.00
- 量 比 1.99
- 振 幅 7.14%
- 历史最低 0.92
- 每 手 1
- 风险率 1.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio
<p>Mainz Biomed的ColoAlert®结直肠癌DNA检测被德国数字健康平台DoctorBox纳入其服务组合，标志着公司在欧洲增长战略中的重要进展。通过与DoctorBox的合作，ColoAlert®在家即可使用，使早期检测更加便捷，降低了筛查障碍，强调了创新个性化预防医学的重要性。</p>
12-02 13:01
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
Mainz Biomed and OncoVanguard8 have signed an MOU to introduce ColoAlert®, a DNA-based colorectal cancer screening test, to South America, starting with Peru. The collaboration aims to address the high prevalence of CRC in Peru, Colombia, and Ecuador, with an estimated 17,000 new cases annually. The rollout is expected to enhance early detection and align with public health initiatives. The MOU outlines commercial, legal, and regulatory terms for...
11-18 13:01
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 208.1% to $27.33...
11-13 20:06
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
Mainz Biomed, a molecular genetics diagnostic company, will participate in MEDICA 2025, a leading global healthcare trade show in Düsseldorf, Germany. The Company will showcase its ColoAlert®, a non-invasive test for early colorectal cancer detection, and other diagnostic solutions. MEDICA attracts thousands of exhibitors and visitors, fostering innovation and collaboration in healthcare. Mainz Biomed aims to strengthen partnerships and raise awa...
11-12 13:01
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
Mainz Biomed N.V. will participate in the 38th Annual GARPS conference in Germany to strengthen connections with gastroenterology experts, discuss cancer prevention, and showcase its ColoAlert® colorectal cancer detection product. The event offers opportunities for collaboration and education on early cancer detection. More information is available on the company’s website or via LinkedIn, X, and Facebook.
11-10 13:01
Mainz Biomed to Attend 2025 Maxim Growth Summit
Mainz Biomed, a molecular genetics diagnostic company focused on early cancer detection, announced its participation in the 2025 Maxim Growth Summit, scheduled for October 22-23 at The Hard Rock Hotel NYC. The prestigious event will gather industry leaders, innovators, and institutions to discuss latest trends across multiple sectors, featuring keynote speakers Larry Kudlow and Christopher Ruddy, and roundtable discussions with CEOs from small an...
10-15 13:01
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
Mainz Biomed will participate in the World Endoscopy Organization's CRC Screening Committee meeting on October 3, 2025, in Berlin. Dr. Lena Krammes will present findings from the eAArly DETECT study, highlighting RNA-based stool testing's potential in early CRC detection and prevention. The test showed 97% sensitivity and specificity for CRC, 82% for advanced adenomas, and 100% for those with high-grade dysplasia. Mainz Biomed emphasizes its comm...
09-30 12:01
Mainz Biomed Launches ColoAlert Colorectal Cancer Test In Switzerland
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the commercial launch of its flagship
09-23 20:08
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
Mainz Biomed announced the commercial launch of its colorectal cancer screening product, ColoAlert®, in Switzerland. Key achievements include a partnership with labor team, regulatory approval from Swissmedic, and successful technology transfer enabling local processing. The company is also progressing its eAArly DETECT study, aiming to complete enrollment by year-end 2025.
09-23 12:01
Mainz Biomed's ColoAlert Receives MHRA Approval For Colorectal Cancer Screening In The UK
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert® has received official
09-02 20:11
